Pharmaceutical prices rise despite government subsidy efforts

Despite government promises to lower costs, pharmaceutical prices in Serbia rose by 7.8 percent in September compared to the previous year. Former President Aleksandar Vučić had announced a relief package involving 12.3 billion dinars (approximately 104.8 million euros) to reduce patient co-payments and expand the list of state-subsidized prescription drugs. Measures included lowering co-payments for certain medications and adding 18 new prescription drugs to the state-covered list.

Economists offer varying perspectives on why prices continue to rise, suggesting that pharmaceutical companies may be offsetting lost profits by increasing prices on products not affected by subsidies. Some critics have characterized the announced price reductions as primarily political maneuvers.

In a related context regarding consumer savings, experts suggest that patients can reduce costs by asking pharmacists for generic alternatives. Generic drugs contain the same active ingredients as original brand-name medications but are often significantly cheaper. This strategy is particularly beneficial for individuals requiring long-term, regular treatments.